Skip to main content
Funding round raises $53M for Finch Therapeutics
8/23/2019

Finch Therapeutics, which is developing a microbiome treatment indicated for recurrent Clostridium difficile infections, gained $53 million in additional capital that will support the company's goals of advancing its clinical asset, CP101, to a potentially pivotal readout.

Full Story: